Modest, Dominik Paul
Heinemann, Volker
Schütt, Philipp
Angermeier, Stefan
Haberkorn, Mike
Waidmann, Oliver
Graeven, Ullrich
Wille, Kai
Kunzmann, Volker
Henze, Larissa
Constantin, Christian
de Wit, Maike
Denzlinger, Claudio
Ballhausen, Alexej
Kurreck, Annika
Jelas, Ivan
Alig, Annabel Helga Sophie
Stahler, Arndt
Stintzing, Sebastian
Oettle, Helmut
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 2 April 2024
Accepted: 31 May 2024
First Online: 1 July 2024
Declarations
:
: UG: honoraria/Advisory role: Boehringer INgelheim, AstraZeneca, Bristol-Myers-Squibb, MSD, Sanofi, Fujifilm, Novartis, Amgen. Travel support: GSK, Boehringer-Ingelheim, Amgen, Merck KGaA AHSA: Honoraria: MSD, Merck CD: Honoraria: Abbvie, Bayer, Celgene, Incyte, Janssen, Novartis HO: research funding: Bristol, Servier SS: honoraria: Amgen, AstraZeneca, Bayer, BMS, ESAI, Leo Pharma, Lilly, Merck, MSD, PierreFabre, Roche, Sanofi, Servier, Taiho, Takeda. Research funding: Merck, Pierre Fabre, Servier, Roche, MSD, Novartis, Biontech, ISofol, Mirati, Amgen AK: Honoraria: Merck AS: Honoraria: Roche, Servier, Taiho, Amgen, Pfizer, Lilly, Merck OW: honoraria: Amgen, Bayer, BMS, Celgene, Eisai, Incyte, Ipsen, MerckSerono, MSD, Novartis, Roche, Servier, AstraZeneca. Travel support: Abbvie, Bayer, BMS, Gilead, Ipsen, Medac, Merck. research funding (inst): Merck VH: Honoraria: Merck, Amgen, Roche, Sanofi, Sirtex, Servier, Pfizer, Pierre-Fabre, AstraZeneca, BMS; MSD, Novartis, Boehringer-INgelheim, Celgene, Terumo, Oncosil, Seagen. Support to institution: Merck, Amgen, Roche, Sanofi, Pfizer, Boeringer-Ingelheim, Sirtex, Servier DPM: Honoraria: Merck, Amgen, Servier, AstraZenenca, MSD, Sanofi, Lilly, Pierre-Fabre, Seagen, Onkowissen, IKF, MCI-Deutschland, Jörg Eickeler Veranstaltungen, Taiho, Takeda, Medscape, Cor2ED, G1, 21up, FOMF, Aptitude, GSK. Travel support: Merck, Amgen, Servier. Research funding (inst): Servier, Amgen
: Researchers should provide a scientifically sound proposal directed to „info@aio-studien-ggmbh.de" for approval to gain access to the requested data. Shared data are only to be used to achieve aims of the approved proposal.
: IPart of the data of this manuscript have been presented as poster presentation at the ESMO Annual Meeting 2022.
: Information that will be considered for disclosure includes individual participant data that underlie the results reported in this article (text, tables, figures, and appendices). Additionally, study protocol, statistical analysis plan and analytic code can be made available. All data shared must be anonymised to protect the privacy of the patients who participated in the trial, in accordance with applicable laws and regulations and in compliance with the International Council for Harmonisation and Good Clinical Practice (ICH/GCP).